CA2906830C - Hepcidin analogues and uses therof - Google Patents
Hepcidin analogues and uses therof Download PDFInfo
- Publication number
- CA2906830C CA2906830C CA2906830A CA2906830A CA2906830C CA 2906830 C CA2906830 C CA 2906830C CA 2906830 A CA2906830 A CA 2906830A CA 2906830 A CA2906830 A CA 2906830A CA 2906830 C CA2906830 C CA 2906830C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- pharmaceutically acceptable
- solvate
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800048P | 2013-03-15 | 2013-03-15 | |
| US201361800284P | 2013-03-15 | 2013-03-15 | |
| US61/800,284 | 2013-03-15 | ||
| US61/800,048 | 2013-03-15 | ||
| PCT/US2014/030352 WO2014145561A2 (en) | 2013-03-15 | 2014-03-17 | Hepcidin analogues and uses therof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2906830A1 CA2906830A1 (en) | 2014-09-18 |
| CA2906830C true CA2906830C (en) | 2021-07-06 |
Family
ID=51538499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2906830A Active CA2906830C (en) | 2013-03-15 | 2014-03-17 | Hepcidin analogues and uses therof |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9822157B2 (enExample) |
| EP (2) | EP4091624A1 (enExample) |
| JP (2) | JP6525471B2 (enExample) |
| KR (1) | KR102236829B1 (enExample) |
| CN (1) | CN105451755B (enExample) |
| AU (2) | AU2014232954B2 (enExample) |
| CA (1) | CA2906830C (enExample) |
| DK (1) | DK2968443T3 (enExample) |
| ES (1) | ES2901704T3 (enExample) |
| HR (1) | HRP20211911T1 (enExample) |
| HU (1) | HUE057168T2 (enExample) |
| IL (1) | IL241043B (enExample) |
| LT (1) | LT2968443T (enExample) |
| NZ (1) | NZ712029A (enExample) |
| PL (1) | PL2968443T3 (enExample) |
| PT (1) | PT2968443T (enExample) |
| RS (1) | RS62633B1 (enExample) |
| SG (2) | SG11201507226YA (enExample) |
| SI (1) | SI2968443T1 (enExample) |
| WO (1) | WO2014145561A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014013697A2 (pt) | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| KR20170002414A (ko) | 2014-04-07 | 2017-01-06 | 멀겐져 바이오텍, 아이엔씨. | 헵시딘 모방 펩티드 및 그 용도 |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| AU2015279571A1 (en) * | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| JP2020504160A (ja) * | 2017-01-18 | 2020-02-06 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 鉄過剰症を治療するための組成物及び方法 |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
| US20220105120A1 (en) * | 2019-02-08 | 2022-04-07 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting inosine monophosphate dehydrogenase |
| WO2020163412A1 (en) * | 2019-02-08 | 2020-08-13 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting inosine monophosphate dehydrogenase |
| AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20220372099A1 (en) | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| KR102521421B1 (ko) * | 2020-01-22 | 2023-04-14 | 연세대학교 산학협력단 | 헤테로키랄 펩티드 복합체 및 이의 자가조립 중간체를 포함한 핵자기공명분광 잔류쌍극결합 측정용 조성물 |
| CA3181577A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thieno pyrimidines as ferroportin inhibitors |
| CA3181583A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Methods of use for pyrimidines as ferroportin inhibitors |
| US11746100B2 (en) | 2020-04-28 | 2023-09-05 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
| CN111560051B (zh) * | 2020-05-26 | 2022-11-25 | 大连工业大学 | 一种具有促铁吸收活性的虾源九肽及其应用 |
| IL299530A (en) * | 2020-07-28 | 2023-02-01 | Protagonist Therapeutics Inc | Psidine is a conjugated mimetic |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2022212696A1 (en) * | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3220871A1 (en) * | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| US20250170216A1 (en) * | 2022-02-02 | 2025-05-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| WO2025207760A1 (en) | 2024-03-27 | 2025-10-02 | Protagonist Therapeutics, Inc. | Formulations of a hepcidin peptide analogue |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
| JPH02306947A (ja) | 1989-05-01 | 1990-12-20 | Monsanto Co | キラルβ―アミノ酸の製造方法 |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| DK0578728T3 (da) | 1991-04-05 | 1999-04-12 | Genentech Inc | Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa |
| US5569741A (en) | 1992-07-27 | 1996-10-29 | Biomeasure, Inc. | Cyclic octapeptide neuromedin B receptor antagonists |
| DK0644772T3 (da) | 1992-11-12 | 2003-06-30 | Sod Conseils Rech Applic | Opioid-peptider |
| US5293050A (en) | 1993-03-25 | 1994-03-08 | International Business Machines Corporation | Semiconductor quantum dot light emitting/detecting devices |
| AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
| GB9516994D0 (en) | 1995-08-18 | 1995-10-18 | Iaf Biochem Int | Solution synthesis of peripheral acting analgestic opioid tetrapeptides |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| US5993811A (en) | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| JP2001509493A (ja) | 1997-07-11 | 2001-07-24 | インナーダイン， インコーポレイテッド | 放射送達構造体の調製およびシール化のための方法およびシステム |
| US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| JP2001523711A (ja) | 1997-11-24 | 2001-11-27 | メルク エンド カムパニー インコーポレーテッド | 細胞接着阻害薬としての環状アミノ酸誘導体 |
| US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
| WO2000006243A2 (en) | 1998-07-28 | 2000-02-10 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
| AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
| AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| MXPA01010231A (es) | 1999-04-12 | 2003-07-21 | Aventis Pharma Ltd | Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina. |
| WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| CA2436326C (en) | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
| WO2002079235A2 (en) | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
| US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
| US20040176293A1 (en) | 2002-12-18 | 2004-09-09 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| EP1618131A2 (en) | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| US20060030053A1 (en) * | 2003-12-19 | 2006-02-09 | Applera Corporation | Methods and systems for protein and peptide evidence assembly |
| DOP2005000002A (es) | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
| NZ551934A (en) | 2004-06-24 | 2009-09-25 | Inst Medical W & E Hall | Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins |
| NZ554331A (en) | 2004-09-23 | 2009-04-30 | Univ Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US20080300180A1 (en) | 2004-11-30 | 2008-12-04 | Gastrotech Pharma A/S | Growth Hormone Secretagogue Receptor 1A Ligands |
| DK1831699T3 (da) | 2004-12-20 | 2010-03-15 | Antibodyshop As | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme |
| US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| WO2007120883A2 (en) | 2006-04-12 | 2007-10-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| EP2024509A4 (en) | 2006-05-22 | 2010-08-04 | Clinical Genomics Pty Ltd | DETECTION METHOD |
| GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| WO2008140602A2 (en) | 2006-12-07 | 2008-11-20 | The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN |
| PE20130588A1 (es) * | 2007-02-02 | 2013-05-21 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| ES2465223T3 (es) | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| US8313950B2 (en) * | 2007-05-21 | 2012-11-20 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| JP2011501941A (ja) | 2007-07-06 | 2011-01-20 | バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ | Ｉｌ−２３レセプターのアンタゴニストおよびその使用 |
| CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
| CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
| EP2352762A1 (en) | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2010065815A2 (en) * | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
| ES2525179T3 (es) | 2009-04-08 | 2014-12-18 | Takeda Pharmaceutical Company Limited | Derivado de neuromedina U |
| TWI578992B (zh) * | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| CA2787331A1 (en) | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
| US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
| JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| US20130236977A1 (en) * | 2010-05-24 | 2013-09-12 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
| IT1406051B1 (it) | 2010-08-05 | 2014-02-06 | D M G Italia S R L | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| ES2763404T3 (es) | 2010-08-11 | 2020-05-28 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
| EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| WO2012101599A2 (en) | 2011-01-27 | 2012-08-02 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
| US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| CA2839408A1 (en) | 2011-06-14 | 2012-12-20 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| BR112014013697A2 (pt) | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| US9238676B2 (en) | 2012-05-17 | 2016-01-19 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| WO2013177432A1 (en) | 2012-05-23 | 2013-11-28 | The University Of Chicago | Methods of treating obesity |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP2956154A4 (en) | 2013-02-15 | 2016-07-27 | Srx Cardio Llc | TYPE 9 (PCSK9) PROPYTEIN CONVERTASE SUBTILISINE / KEXINE PROPAGINE CONVERTASE BINDING LIGANDS FOR USE IN MODULATION OF SERIES LEVELS OF LOW DENSITY LIPOPROTEIN (LDL) |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
| US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
| PT3013351T (pt) | 2013-06-24 | 2020-01-17 | Canbas Co Ltd | Péptidos e peptidomiméticos em utilizações e tratamentos combinados para subpopulações de pacientes com cancro |
| CA2916492A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
| JP2016534043A (ja) | 2013-10-09 | 2016-11-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 炎症促進性サイトカインのダウンレギュレーションに有用なグアニル酸シクラーゼのアゴニスト |
| WO2015112700A1 (en) | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
| KR20170002414A (ko) | 2014-04-07 | 2017-01-06 | 멀겐져 바이오텍, 아이엔씨. | 헵시딘 모방 펩티드 및 그 용도 |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| AU2015279571A1 (en) | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
| US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
| WO2016115168A1 (en) | 2015-01-12 | 2016-07-21 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
| WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
| WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| HK1257747A1 (zh) | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| WO2017068089A2 (en) | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| US20190264197A1 (en) | 2016-07-27 | 2019-08-29 | Protagonist Therapeutics, Inc. | Disulfide-rich peptide libraries and methods of use thereof |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| AU2017324446A1 (en) | 2016-09-06 | 2019-03-28 | La Jolla Pharmceutical Company | Methods of treating iron overload |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| CA3046171A1 (en) | 2016-12-06 | 2018-06-14 | Stichting Voor De Technische Wetenschappen | Multicyclic peptides and methods for their preparation |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| JP2020505352A (ja) | 2017-01-18 | 2020-02-20 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用 |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3135024A1 (en) | 2019-03-28 | 2020-10-01 | Protagonist Therapeutics, Inc. | Methods for synthesizing .beta.-homoamino acids |
| AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20220372099A1 (en) | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4093421A4 (en) | 2020-01-10 | 2024-01-10 | Protagonist Therapeutics, Inc. | Methods for treating inflammatory bowel diseases with alpha4beta7 integrin antagonists |
| WO2021146458A1 (en) | 2020-01-15 | 2021-07-22 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| IL299530A (en) | 2020-07-28 | 2023-02-01 | Protagonist Therapeutics Inc | Psidine is a conjugated mimetic |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2022212696A1 (en) | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4314014A4 (en) | 2021-04-01 | 2025-03-05 | Protagonist Therapeutics, Inc. | HEPCIDIN MIMETICS CONJUGATES |
| WO2022212698A1 (en) | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3220871A1 (en) | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| JP2024525723A (ja) | 2021-07-14 | 2024-07-12 | ヤンセン バイオテツク，インコーポレーテツド | インターロイキン－２３受容体の二環式ペプチド阻害剤 |
| CA3226539A1 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor |
| US20250179196A1 (en) | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| US20250170216A1 (en) | 2022-02-02 | 2025-05-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4472995A4 (en) | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| EP4536683A4 (en) | 2022-06-07 | 2026-06-10 | Protagonist Therapeutics Inc | HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE |
| WO2024011188A1 (en) | 2022-07-07 | 2024-01-11 | Protagonist Therapeutics, Inc. | Combination therapy for treatment of iron overload diseases |
-
2014
- 2014-03-17 EP EP21199316.7A patent/EP4091624A1/en active Pending
- 2014-03-17 WO PCT/US2014/030352 patent/WO2014145561A2/en not_active Ceased
- 2014-03-17 SI SI201431924T patent/SI2968443T1/sl unknown
- 2014-03-17 CN CN201480024873.4A patent/CN105451755B/zh active Active
- 2014-03-17 SG SG11201507226YA patent/SG11201507226YA/en unknown
- 2014-03-17 AU AU2014232954A patent/AU2014232954B2/en active Active
- 2014-03-17 PL PL14763104T patent/PL2968443T3/pl unknown
- 2014-03-17 NZ NZ712029A patent/NZ712029A/en unknown
- 2014-03-17 ES ES14763104T patent/ES2901704T3/es active Active
- 2014-03-17 JP JP2016503378A patent/JP6525471B2/ja active Active
- 2014-03-17 PT PT147631048T patent/PT2968443T/pt unknown
- 2014-03-17 SG SG10201707622XA patent/SG10201707622XA/en unknown
- 2014-03-17 DK DK14763104.8T patent/DK2968443T3/da active
- 2014-03-17 LT LTEPPCT/US2014/030352T patent/LT2968443T/lt unknown
- 2014-03-17 HU HUE14763104A patent/HUE057168T2/hu unknown
- 2014-03-17 US US14/775,469 patent/US9822157B2/en active Active
- 2014-03-17 RS RS20211476A patent/RS62633B1/sr unknown
- 2014-03-17 KR KR1020157028714A patent/KR102236829B1/ko active Active
- 2014-03-17 HR HRP20211911TT patent/HRP20211911T1/hr unknown
- 2014-03-17 CA CA2906830A patent/CA2906830C/en active Active
- 2014-03-17 EP EP14763104.8A patent/EP2968443B1/en active Active
-
2015
- 2015-09-02 IL IL241043A patent/IL241043B/en active IP Right Grant
-
2017
- 2017-09-29 US US15/720,333 patent/US20180100004A1/en not_active Abandoned
- 2017-11-30 US US15/828,214 patent/US10030061B2/en active Active
-
2018
- 2018-05-18 JP JP2018096211A patent/JP6722227B2/ja active Active
- 2018-07-17 US US16/037,982 patent/US10442846B2/en active Active
- 2018-11-05 AU AU2018260800A patent/AU2018260800B2/en active Active
-
2019
- 2019-02-28 US US16/289,451 patent/US10501515B2/en active Active
-
2020
- 2020-11-16 US US17/099,308 patent/US11807674B2/en active Active
-
2023
- 2023-09-28 US US18/477,490 patent/US12269856B2/en active Active
-
2025
- 2025-03-04 US US19/069,557 patent/US20250340608A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269856B2 (en) | Hepcidin analogues and uses thereof | |
| KR20230053615A (ko) | 접합된 헵시딘 모방체 | |
| EP3749345A1 (en) | Conjugated hepcidin mimetics | |
| CA2953721A1 (en) | Hepcidin and mini-hepcidin analogues and uses therof | |
| WO2017117411A1 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| HK40084564A (en) | Hepcidin analogues and uses thereof | |
| NZ751741B2 (en) | Hepcidin analogues and uses therof | |
| HK1220112B (en) | Hepcidin analogues and uses therof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190315 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250225 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250807 Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250807 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260219 |